Clinical significance of folic acid metabolic gene detection in methotrexate treatment of leukemia

Weiwei SONG; Yuehua HUANG; Lan WANG; Jing TANG; Qiantai MAO; Jianxin WANG; Chao AI.
China Pharmacy ; (12): 1269-1273, 2022.
Artículo en Zh | WPRIM | ID: wpr-924083

Documentos relacionados

  1. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
  2. Would they accept it? An interview study to identify barriers and facilitators to user acceptance of a prescribing advice service.
  3. Insights into the Inhibitory Mechanisms of the Covalent Drugs for DNMT3A.
  4. FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells.
  5. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
  6. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
  7. Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid Leukemia.
  8. VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.
  9. VEXAS: where do we stand 2 years later?
  10. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.